Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Understanding Differences in Sex Characteristics in Patients Admitted for Neuromyelitis Optica Spectrum Disorder in the United States
Autoimmune Neurology
P11 - Poster Session 11 (5:30 PM-6:30 PM)
NMOSD is an immune-mediated neurological disease diagnosed based on clinical, radiological and serology findings. Due to females being mostly affected, there is paucity of data about characteristics in males and how these compare to females.

To identify the differences associated with birth-assigned sex among individuals with Neuromyelitis Optica Spectrum Disorder (NMOSD).

Using the National Inpatient Sample (NIS) database from 2016-2020, we queried patients admitted for NMOSD based on ICD-10 codes. We compared the prevalence of comorbidities between males and females.
A total of 9,300 patients were hospitalized for NMOSD between 2016 and 2020, 21% male and 79% female. Most patients were between 30-59 years of age (53.1% males vs 59.6% females). Mean age for males and females was 41.08 and 42.7 years, respectively (p<0.01). Males had higher prevalence of comorbidities such as hyperlipidemia (17.0% vs 13.8% females, p<0.01), hypertension (33.0% vs 27.4% females, p<0.01), drug abuse (3.4% vs 2% females, p<0.01), smoking (35.3% vs 22.9% females, p<0.01), previous myocardial infarction (2.1% vs 1.3% females, p=0.012), and chronic kidney disease (4.9% vs 1.9% females, p<0.01). Females had higher prevalence of asthma (9.1% vs 5.9% males, p<0.01), depression (16.4% vs 10.3% males, p<0.01), systemic lupus erythematosus (5.7% vs 2.6% males, p<0.01), multiple sclerosis (17.8% vs 13.1% males, p<0.01), prior stroke (3.3% vs 2.1% males, p<0.01), and obesity (16.4% vs 13.7% males, p<0.01). Charlson Comorbidity Index score was 1.40 in females and 1.14 in Males, (p<0.01).
Our research showed statistically significant differences in comorbidities amongst males and females admitted with NMOSD. Understanding sex differences in NMOSD patients in association with specific comorbidities can help ascertain risk, severity, or prognosis, and serve as a basis for future research and treatment.
Maya Gabel, MD (University of Miami)
Dr. Gabel has nothing to disclose.
Prince K. Pekyi-Boateng, MBBS (Korle-Bu Teaching Hospital) Dr. Pekyi-Boateng has nothing to disclose.
Fiifi Duodu, MD (Korle-Bu Teaching Hospital Medical department) Dr. Duodu has nothing to disclose.
Nana Y. Kyei-Frimpong, MD (37 Military Hospital) Dr. Kyei-Frimpong has nothing to disclose.
Nana Boakye Agyeman Badu-Prempeh (Johns Hopkins Bloomberg School of Public health) Dr. Badu-Prempeh has nothing to disclose.
Shaheen Sombans, MBBS (Fernandez Foundation) Dr. Sombans has nothing to disclose.
SHER DHILLON No disclosure on file
Balkiranjit Dhillon No disclosure on file
Patrick Pekyi-Boateng (Kwame Nkrumah University of Science and Technology, School of Medical Sciences) No disclosure on file
Jeffrey Parker No disclosure on file
Salini Ajitha No disclosure on file
Hemamalini Sakthivel No disclosure on file
Kamleshun Ramphul No disclosure on file